Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies

European Neuropsychopharmacology

Volumn 21, Issue 8, 2011, Pages 600-620

  Zuddas, Alessandro ^a   Zanni, Roberta ^a   Usala, Tatiana ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Aripiprazole; Bipolar disorder; Conduct disorder; Olanzapine; Pervasive developmental disorders; Quetiapine; Risperidone

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BROMOCRIPTINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PENTOXIFYLLINE; PIMOZIDE; PIRACETAM; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ABDOMINAL PAIN; ADOLESCENT DISEASE; AGGRESSION; AGRANULOCYTOSIS; AKATHISIA; AUTISM; BIPOLAR MANIA; CHILDHOOD DISEASE; CONSTIPATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISRUPTIVE BEHAVIOR; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSPEPSIA; DYSTONIA; FATIGUE; FATTY LIVER; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; GRANULOCYTOPENIA; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; IRRITABILITY; LIVER INJURY; LOW DRUG DOSE; MENTAL DISEASE; MYOCARDITIS; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARKINSONISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; TORSADE DES POINTES; TREMOR; VOMITING; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; DEVELOPMENTAL DISABILITIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959887445     PISSN: 0924977X     EISSN: 0924977X     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.04.001     Document Type: Review

References (127)

1. Acquaviva E., Legleye S., Auleley G.R., Deligne J., Carel D., Falissard B.B. Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry 2009, 17(9):72.
2. Akhondzadeh S., Tajdar H., Mohammadi M.R., Mohammadi M., Nouroozinejad G.H., Shabstari O.L., Ghelichnia H.A. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum. Dev. 2008, 39:237-245.
3. Akhondzadeh S., Fallah J., Mohammadi M.R., Imani R., Mohammadi M., Salehi B., Ghanizadeh A., Raznahan M., Mohebbi-Rasa S., Rezazadeh S.A., Forghani S. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010, 34:32-36.
4. Alvarez P.A., Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr. Drug Saf. 2010, 5:97-104.
5. Aman M.G., De Smedt G., Derivan A., Lyons B., Findling R.L. Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am. J. Psychiatry 2002, 159(8):1337-1346.
6. Aman M.G., Hollway J.A., McDougle C.J., Scahill L., Tierney E., McCracken J.T., Arnold L.E., Vitiello B., Ritz L., Gavaletz A., Cronin P., Swiezy N., Wheeler C., Koenig K., Ghuman J.K., Posey D.J. Cognitive effects of risperidone in children with autism and irritable behavior. J. Child Adolesc. Psychopharmacol. 2008, 18:227-236.
7. Aman M.G., McDougle C.J., Scahill L., Handen B., Arnold L.E., Johnson C., Stigler K.A., Bearss K., Butter E., Swiezy N.B., Sukhodolsky D.D., Ramadan Y., Pozdol S.L., Nikolov R., Lecavalier L., Kohn A.E., Koenig K., Hollway J.A., Korzekwa P., Gavaletz A., Mulick J.A., Hall K.L., Dziura J., Ritz L., Trollinger S., Yu S., Vitiello B., Wagner A. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48:1143-1154. the Research Units on Pediatric Psychopharmacology Autism Network.
8. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Text Revision. Washington DC. Fourth Ed.
9. Anderson G.M., Scahill L., McCracken J.T., McDougle C.J., Aman M.G., Tierney E., Arnold L.E., Martin A., Katsovich L., Posey D.J., Shah B., Vitiello B. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol. Psychiatry 2007, 61:545-550.
10. Aparasu R.R., Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr. Med. Res. Opin. 2007, 23:49-56.
11. Arango C., Robles O., Parellada M., Fraguas D., Ruiz-Sancho A., Medina O., Zabala A., Bombín I., Moreno D. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur. Child Adolesc. Psychiatry 2009, 18:418-428.
12. Arman S., Sadramely M.R., Nadi M., Koleini N. A randomized, double-blind placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med. J. 2008, 29:1130-1134.
13. Armenteros J.L., Lewis J.E., Davalos M. Risperidone augmentation for treatment-resistant aggression in attention deficit/hyperactivity disorder: a placebo-controlled pilot study. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:558-565.
14. Arnold L.E., Farmer C., Kraemer H.C., Davies M., Witwer A., Chuang S., DiSilvestro R., Mcdougle C.J., Mccracken J., Vitiello B., Aman M.G., Scahill, Posey D.J., Swiezy N.B. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J. Child Adolesc. Psychopharmacol. 2010, 20:83-93.
15. Barzman D.H., DelBello M.P., Adler C.M., Stanford K.E., Strakowski S.M. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J. Child Adolesc. Psychopharmacol. 2006, 16:665-670.
16. Biederman J., Mick E., Hammerness P., Harpold T., Aleardi M., Dougherty M., Wozniak J. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol. Psychiatry 2005, 58:589-594.
17. Birkenaes A.B., Birkeland K.I., Friis S., Opjordsmoen S., Andreassen O.A. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions. J. Clin. Psychopharmacol. 2009, 29:109-116.
18. Birmaher B. Longitudinal course of pediatric bipolar disorder. Am. J. Psychiatry 2007, 164:537-539.
19. Blair J., Scahill L., State M., Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J. Am. Acad. Child Adolesc. Psychiatry 2005, 44:73-79.
20. Bloch M.H., Landeros-Weisenberger A., Kelmendi B., Coric V., Bracken M.B., Leckman J.F. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol. Psychiatry 2006, 11:622-632.
21. Bruggeman R., van der Linden C., Buitelaar J.K., Gericke G.S., Hawkridge S.M., Temlett J.A. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J. Clin. Psychiatry 2001, 62:50-56.
22. Brunelle J., Consoli A., Tanguy M.L., Huynh C., Perisse D., Deniau E., Guilé J.M., Gérardin P., Cohen D. Phenomenology, socio-demographic factors and outcome upon discharge of manic and mixed episodes in hospitalized adolescents: a chart review. Eur. Child Adolesc. Psychiatry 2009, 18:185-193.
23. Buitelaar J.K., Van Der Gaag R.J., Cohen-Kettenis P., Melman C.T. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J. Clin. Psychiatry 2001, 62:239-248.
24. Calarge C.A., Ellingrod V.L., Acion L., Miller D.D., Moline J., Tansey M.J., Schlechte J.A. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet. Genomics 2009, 19:373-382.
25. Carlson C., Hornbuckle K., DeLisle F., Kryzhanovskaya L., Breier A., Cavazzoni P. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur. Neuropsychopharmacol. 2006, 16:366-375.
26. Castro-Fornieles J., Parellada M., Soutullo C.A., Baeza I., Gonzalez-Pinto A., Graell M., Paya B., Moreno D., de la Serna E., Arango C. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J. Child Adolesc. Psychopharmacol. 2008, 18:327-336.
27. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Erlbaum, Hillsdale, NJ. 2nd ed.
28. Connor D.F., McLaughlin T.J., Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J. Child Adolesc. Psychopharmacol. 2008, 18:140-156.
29. Correll C.U. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47:9-20.
30. Correll C.U., Carlson H.E. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 2006, 45:771-791.
31. Correll C.U., Kane J.M. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J. Child Adolesc. Psychopharmacol. 2007, 17:647-656.
32. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry 2008, 21:151-156.
33. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009, 302:1765-1773.
34. DelBello M.P., Schwiers M.L., Rosenberg H.L., Strakowski S.M. A doubleblind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41:1216-1223.
35. DelBello M.P., Kowatch R.A., Adler C.M., Stanford K.E., Welge J.A., Barzman D.H., Nelson E., Strakowski S.M. A double blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J. Am. Acad. Child Adolesc. Psychiatry 2006, 45:305-313.
36. DelBello M.P., Chang K., Welge J.A., Adler C.M., Rana M., Howe M., Bryan H., Vogel D., Sampang S., Delgado S.V., Sorter M., Strakowski S.M. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009, 11:483-493.
37. Dion Y., Annable L., Sandor P., Chouinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2002, 22:31-39.
38. Dollfus S., Petit M., Menard J.F., Lesieur P. Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. J. Autism Dev. Disord. 1992, 22:47-60.
39. Ebbeling C.B., Pawlak D.B., Ludwig D.S. Childhood obesity: public-health crisis, common sense cure. Lancet 2002, 360:473-482.
40. Elbe D., Carandang C.G. Focus on ziprasidone: a review of its use in child and adolescent psychiatry. J. Can. Acad. Child. Adolesc. Psychiatry. 2008, 17:220-229.
41. Findling R.L., McNamara N.K., Branicky L.A., Schluchter M.D., Lemon E., Blumer J.L. A double-blind pilot study of risperidone in the treatment of conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 2000, 39:509-516.
42. Findling R.L., Kusumakar V., Daneman D., Moshang T., Desmedt G., Binder C. Prolactin levels during longterm risperidone treatment in children and adolescents. J. Clin. Psychiatry 2003, 64:1362-1369.
43. Findling R.L., Kauffman R.E., Sallee F.R., Carson W.H., Nyilas M., Mallikaarjun S., Shoaf S.E., Forbes R.A., Boulton D.W., Pikalov A. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J. Clin. Psychopharmacol. 2008, 28:441-446.
44. Findling R.L., Robb A., Nyilas M., Forbes R.A., Jin N., Ivanova S., Marcus R., McQuade R.D., Iwamoto T., Carson W.H. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am. J. Psychiatry 2008, 165:1432-1441.
45. Findling R.L., Nyilas M., Forbes R.A., McQuade R.D., Jin N., Iwamoto T., Ivanova S., Carson W.H., Chang K. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2009, 70:1441-1451.
46. Findling R.L., Johnson J.L., McClellan J., Frazier J.A., Vitiello B., Hamer R.M., Lieberman J.A., Ritz L., McNamara N.K., Lingler J., Hlastala S., Pierson L., Puglia M., Maloney A.E., Kaufman E.M., Noyes N., Sikich L. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J. Am. Acad. Child Adolesc. Psychiatry 2010, 49:583-594.
47. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., Hennekens C.H., Lambert M., Leucht S., Maj M., McIntyre R.S., Naber D., Newcomer J.W., Olfson M., Osby U., Sartorius N., Lieberman J.A. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J. Clin. Psychiatry 2008, 69:514-519.
48. Fraguas D., MerchaÅLn-Naranjo J., Laita P., Parellada M., Moreno D., Ruiz-Sancho A., Cifuentes A., Giráldez M., Arango C. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J. Clin. Psychiatry 2008, 69:1166-1175.
49. Fraguas D., Correll C.U., Merchán-Naranjo J., Rapado-Castro M., Parellada M., Moreno C., Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur. Neuropsychopharmacol 2010, 10.1016/j.euroneuro.2010.07.002.
50. Gao K., Kemp D.E., Ganocy S.J., Gajwani P., Xia G., Calabrese J.R. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J. Clin. Psychopharmacol. 2008, 28:203-209.
51. Geller B.R., Tillman R., Bolhofner K., Zimerman B. Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome. Arch. Gen. Psychiatry 2008, 65:1125-1133.
52. Gerbino-Rosen G., Roofeh D., Tompkins D.A., Feryo D., Nusser L., Kranzler H., Napolitano B., Frederickson A., Henderson I., Rhinewine J., Kumra S. Hematological adverse events in clozapine-treated children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 2005, 44:1024-1031.
53. Gilbert D.L., Batterson J.R., Sethuraman G., Sallee F.R. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J. Am. Acad. Child Adolesc. Psychiatry 2004, 43:206-214.
54. Glassman A.H., Bigger J.T. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry 2001, 158:1774-1782.
55. Gonzalez-Heydrich J., Raches D., Wilens T.E., Leichtner A., Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J. Am. Acad. Child Adolesc. Psychiatry 2003, 42:1227-1233.
56. Goodwin G.M., Martinez-Aran A., Glahn D.C., Vieta E. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur. Neuropsychopharmacol. 2008, 18:787-793.
57. Gothelf D., Apter A., Reidman J., Brand-Gothelf A., Bloch Y., Gal G., Kikinzon L., Tyano S., Weizman R., Ratzoni G. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J. Neural Transm. 2003, 110:545-560.
58. Haas M., Karcher K., Pandina G.J. Treating disruptive behavior disorders with risperidone: a 1-year, openlabel safety study in children and adolescents. J. Child Adolesc. Psychopharmacol. 2008, 18:337-345.
59. Haas M., Delbello M.P., Pandina G., Kushner S., Van Hove I., Augustyns I., Quiroz J., Kusumakar V. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009, 11:687-700.
60. Haas M., Unis A.S., Armenteros J., Copenhaver M.D., Quiroz J.A., Kushner S.F. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J. Child Adolesc. Psychopharmacol. 2009, 19:611-621.
61. Hirschfeld R.M., Weisler R.H., Raines S.R., Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2006, 67:355-362. for the BOLDER Study Group.
62. Hollander E., Wasserman S., Swanson E.N., Chaplin W., Schapiro M.L., Zagursky K., Novotny S. A double blind placebo controlled pilot study of Olanzapine in childhood/adolescent pervasive developmental disorder. J. Child Adolesc. Psychopharmacol. 2006, 16:541-548.
63. Judd L.L., Akiskal H.S. The prevalence and disability of bipolar spectrum disorders in the US population: reanalysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 2003, 73:123-131.
64. Kalverdijk J.J., Tobi H., Van Den Berg P.B., Buiskool J., Wagenaar L., Minderaa R.B. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr. Serv. 2008, 59:554-560.
65. Klein D.J., Cottingham E.M., Sorter M., Barton B.A., Morrison J.A. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am. J. Psychiatry 2006, 163:2072-2079.
66. Koelch M., Prestel A., Singer H., Keller F., Fegert J.M., Schlack R., Hoelling H., Knopf H. Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. J. Child Adolesc. Psychopharmacol. 2009, 19:765-770.
67. Kryzhanovskaya L., Schulz S.C., McDougle C., Frazier J., Dittmann R., Robertson-Plouch C., Bauer T., Xu W., Wang W., Carlson J., Tohen M. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48:60-70.
68. Kumra S., Herion D., Jacobsen L.K., Briguglia C., Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36:701-705. 93.
69. Kumra S., Kranzler H., Gerbino-Rosen G., Kester H.M., DeThomas C., Kafantaris V., Correll C.U., Kane J.M. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol. Psychiatry 2008, 63:524-529.
70. Kumra S., Oberstar J.V., Sikich L., Findling R.L., McClellan J.M., Vinogradov S., Schulz C.S. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr. Bull. 2008, 34:60-71.
71. Laita P., Cifuentes A., Doll A., Llorente C., Cortés I., Parellada M., Moreno D., Ruiz-Sancho A., Graell M., Arango C. Antipsychotic-related abnormal involuntary movements, and metabolic and endocrine side effects in children and adolescents. J. Child. Adolesc. Psychopharmacology. 2007, 17:487-502.
72. Levy S., Mandell D.S., Schultz R.T. Autism. Lancet 2009, 374:1627-1638.
73. Luby J., Mrakotsky C., Stalets M.M., Belden A., Heffelfinger A., Williams M., Spitznagel E. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J. Child Adolesc. Psychopharmacol. 2006, 16:575-587.
74. Lyon G.J., Shprecher D., Coffey B., Kurlan R. Tourette's disorder. Curr. Treat. Options Neurol. 2010, 12:274-286.
75. Malone R.P., Maislin G., Choudhury M.S., Gifford C., Delaney M.A. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41:140-147.
76. Marcus R.N., Owen R., Kamen L., Manos G., McQuade R.D., Carson W.H., Aman M.G. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48:1110-1119.
77. McClellan J., Kowatch R., Findling R.L. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:107-125. Work Group on Quality Issues.
78. McCracken J.T. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005, 162:1361-1369. The Research Units on Pediatric Psychopharmacology Autism Network.
79. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., Arnold L.E., Lindsay R., Nash P., Hollway J., McDougle C.J., Posey D., Swiezy N., Kohn A., Scahill L., Martin A., Koenig K., Volkmar F., Carroll D., Lancor A., Tierney E., Ghuman J., Gonzalez N.M., Grados M., Vitiello B., Ritz L., Davies M., Robinson J., McMahon D. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 2002, 347:314-321. Research Units on Pediatric Psychopharmacology Autism Network.
80. McDougle C.J., Holmes J.P., Carlson D.C., Pelton G.H., Cohen D.J., Price L.H. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch. Gen. Psychiatry 1998, 55:633-641.
81. McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., Arnold L.E., Posey D.J., Martin A., Ghuman J.K., Shah B., Chuang S.Z., Swiezy N.B., Gonzalez N.M., Hollway J., Koenig K., McGough J.J., Ritz L., Vitiello B. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am. J. Psychiatry 2005, 162:1142-1148.
82. Miceli J.J., Tensfeldt T.G., Shiovitz T., Anziano R.J., O'Gorman C., Harrigan R.H. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin. Ther. 2010, 32:472-491.
83. Miceli J.J., Tensfeldt T.G., Shiovitz T., Anziano R., O'Gorman C., Harrigan R.H. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder. Pharmacotherapy 2010, 30:127-135.
84. Miral S., Gencer O., Inal-Emiroglu F.N., Baykara B., Baykara A., Dirik E. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur. Child Adolesc. Psychiatry 2008, 17:1-8.
85. Moreno C., Laje G., Blanco C., Jiang H., Schmidt A.B., Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch. Gen. Psychiatry 2007, 64:1032-1039.
86. Nagaraj R., Singhi P., Malhi P. Risperidone in children with autism: randomized, placebo controlled, double blind study. J. Child Neurol. 2006, 21:450-455.
87. Neuhut R., Lindenmayer J.P., Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J. Child Adolesc. Psychopharmacol. 2009, 19:415-422.
88. Olfson M., Blanco C., Liu L., Moreno C., Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch. Gen. Psychiatry 2006, 63:679-685.
89. Olfson M., Crystal S., Huang C., Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J. Am. Acad. Child Adolesc. Psychiatry 2010, 49:13-23.
90. Owen R., Sikich L., Marcus R.N., Corey-Lisle P., Manos G., McQuade R.D., Carson W.H., Findling R.L. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124:1533-1540.
91. Panagiotopoulos C., Ronsley R., Davidson J. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can. J. Psychiatry. 2009, 54:743-749.
92. Pandina G.J., Bossie C.A., Youssef E., Zhu Y., Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J. Autism Dev. Disord. 2007, 37:367-373.
93. Pathak P., West D., Martin B.C. Weighing the evidence for pediatric antipsychotic use. Psychiatr. Serv. 2010, 61:325.
94. Paus T., Keshavan M., Giedd J.N. Why do many psychiatric disorders emerge during adolescence?. Nat. Rev. Neurosci. 2008, 9:947-957.
95. Penzner J.B., Dudas M., Saito E., Olshanskiy V., Parikh U.H., Kapoor S., Chekuri R., Gadaleta D., Avedon J., Sheridan E.M., Randell J., Malhotra A.K., Kane J.M., Correll C.U. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J. Child Adolesc. Psychopharmacol. 2009, 19:563-573.
96. Posey D.J., Erickson C.A., McDougle C.J. Developing drugs for core social and communication impairment in autism. Child Adolesc. Psychiatr. Clin. N. Am. 2008, 17:787-801.
97. Rani F., Murray M.L., Byrne P.J., Wong I.C. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008, 121:1002-1009.
98. Ratzoni G., Gothelf D., Brand-Gothelf A., Reidman J., Kikinzon L., Gal G., Phillip M., Apter A., Weizman R. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41:337-343.
99. Reyes M., Buitelaar J., Toren P., Augustyns I., Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am. J. Psychiatry 2006, 163:402-410.
100. Rezaei V., Mohammadi M.R., Ghanizadeh A., Sahraian A., Tabrizi M., Rezazadeh S.A., Akhondzadeh S. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010, 34:1269-1272.
101. Roke Y., van Harten P.N., Boot A.M., Buitelaar J.K. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J. Child Adolesc. Psychopharmacol. 2009, 19:403-414.
102. Sallee F.R., Kurlan R., Goetz C.G., Singer H., Scahill L., Law G., Dittman V.M., Chappell P.B. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J. Am. Acad. Child. Adolesc. Psychiatry. 2000, 39:292-299.
103. Scahill L., Leckman J.F., Schultz R.T., Katsovich L., Peterson B.S. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60:1130-1135.
104. Shaw P., Sporn A., Gogtay N., Overman G.P., Greenstein D., Gochman P., Tossell J.W., Lenane M., Rapoport J.L. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch. Gen. Psychiatry 2006, 63:721-730.
105. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I., Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114:e634-e641.
106. Sikich L., Hamer R.M., Bashford R.A., Sheitman B.B., Lieberman J.A. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacol. 2004, 29:133-145.
107. Sikich L., Frazier J.A., McClellan J., Findling R.L., Vitiello B., Ritz L., Ambler D., Puglia M., Maloney A.E., Michael E., De Jong S., Slifka K., Noyes N., Hlastala S., Pierson L., McNamara N.K., Delporto-Bedoya D., Anderson R., Hamer R.M., Lieberman J.A. Double-blind comparison of antipsychotics in early onset schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2008, 165:1420-1431.
108. Silke B., Campbell C., King D.J. The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability. J. Psychopharmacol. 2002, 16:355-360.
109. Smith G.C., Vickers M.H., Cognard E., Shepherd P.R. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res. 2009, 115:30-40.
110. Snyder R., Turgay A., Aman M., Binder C., Fisman S., Carroll A. Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41:1026-1036.
111. Soutullo C.A., Chang K.D., Diez-Suarez A., Figueroa-Quintana A., Escamilla-Canales I., Rapado-Castro M., Ortuño F. Bipolar disorder in children and adolescents: international perspective on epidemiology and phenomenology. Bipolar Disord. 2005, 7:497-506.
112. Staller J. The effect of long-term antipsychotic treatment on prolactin. J. Child Adolesc. Psychopharmacol. 2006, 16:317-326.
113. Stringaris A., Santosh P., Leibenluft E., Goodman R. Youth meeting symptom and impairment criteria for mania-like episodes lasting less than four days: an epidemiological enquiry. J. Child. Psychol. Psychiatry. 2010, 51:31-38.
114. Taylor E. Managing bipolar disorders in children and adolescents. Nat. Rev. Neurol. 2009, 5:484-491.
115. Thase M.E., Macfadden W., Weisler R.H., Chang W., Paulsson B., Khan A., Calabrese J.R. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 2006, 26:600-609. BOLDER II Study Group.
116. Tohen M., Kryzhanovskaya L., Carlson G., Delbello M., Wozniak J., Kowatch R., Wagner K., Findling R., Lin D., Robertson-Plouch C., Xu W., Dittmann R.W., Biederman J. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am. J. Psychiatry 2007, 164:1547-1556.
117. Tramontina S., Zeni C.P., Ketzer C.R., Pheula G.F., Narvaez J., Rohde L.A. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J. Clin. Psychiatry 2009, 70:756-764.
118. Troost P.W., Lahuis B.E., Steenhuis M.P., Ketelaars C.E., Buitelaar J.K., van Engeland H., Scahill L., Minderaa R.B., Hoekstra P.J. Long term effects of Risperidone in children with autism spectrum disorders: a placebo discontinuation study. J. Am. Acad. Child Adolesc. Psychiatry 2005, 44:1137-1144.
119. Troost P.W., Lahuis B.E., Hermans M.H., Buitelaar J.K., van Engeland H., Scahill L., Minderaa R.B., Hoekstra P.J. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J. Clin. Psychopharmacol. 2007, 27:52-57.
120. Turgay A., Binder C., Snyder R., Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002, 110:e34.
121. Van Bellinghen M., De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J. Child Adolesc. Psychopharmacol. 2001, 11:5-13.
122. Verdoux H., Tournier M., Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr. Scand. 2010, 121:4-10.
123. Vitiello B., Correll C., van Zwieten-Boot B., Zuddas A., Parellada M., Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur. Neuropsychopharmacol. 2009, 19:629-635.
124. Wehmeier P.M., Schuler-Springorum M., Heiser P., Remschmidt H. Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine. J. Child Adolesc. Psychopharmacol. 2004, 14:267-271.
125. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 1978, 133:429-435.
126. Zito J.M., Safer D.J., de Jong-van de Berg L.T., Janhsen K., Fegert J.M., Gardner J.F., Glaeske G., Valluri S.C. A three-country comparison of psychotropic medication prevalence in youth. Child. Adolesc. Psychiatry. Ment. Health. 2008, 2(26):1-18.
127. Zuddas A., Di Martino A., Muglia P., Cianchetti C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J. Child Adolesc. Psychopharmacol. 2000, 10:79-90.